Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$16.85 USD

16.85
7,402,043

+0.13 (0.78%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $16.76 -0.09 (-0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 13.59% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unveiling Viatris (VTRS) Q1 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Viatris Q1 Earnings Release: What's in Store for the Stock?

by Zacks Equity Research

VTRS' Q1 results are likely to gain from new product launches in all major geographies.

Zacks Equity Research

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Viatris to Pay $335 Million for Settlement of Opioid-Related Claims

by Zacks Equity Research

VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.

Zacks Equity Research

Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings

by Zacks Equity Research

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges

by Zacks Equity Research

VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. Stock down.

Zacks Equity Research

Theravance's Q4 Loss In Line With Estimates, Sales Beat

by Zacks Equity Research

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.

Zacks Equity Research

Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of -5.26% and 2.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?